News Archive - Page 4 of 6

Company update on Ultimovacs after the release of clinical data, has been published by Edison Investment Research

“Yesterday, Ultimovacs reported the first results from a Phase I trial of UV1 in advanced melanoma in combination with Keytruda. […]

“Det norske selskapet Ultimovacs står bak kreftvaksinen UV1. Over år ha selskapet forsket på vaksinen som er en peptid-basert vaksine, […]

“Ultimovacs UV1 kreftvaksine i kombinasjon med immunterapien Keytruda har effekt på 60 prosent av pasientene med avansert føflekkreft. 60 prosent […]

“It would seem like Ultimovacs is on to something with its cancer vaccine UV1. New data from their phase I […]

13 april, 2021 “The American Association for Cancer Research kicked off its annual meeting last week to put the top […]

26 februari, 2021 “After presenting their 2020 Q4 report, Ultimovacs immediately turned their attention back to 2021 by announcing the […]

“2020 was a year of key clinical advancements for Ultimovacs. In particular, the company’s already extensive development program with top […]

“Ultimovacs starter fase 2-studie for pasienter med alvorlig eggstokkreft – rekrutterer norske pasienter Ultimovacs har i den siste tiden startet […]

https://www.edisongroup.com/publication/phase-ii-data-from-500-patients-over-2022-23/28660

“Ultimovacs announced yesterday that it will be participating in a phase II study in collaboration with AstraZeneca, along with the […]